Study summary

The first new IPF drug in over a decade slowed lung function decline

FIBRONEER-IPF trial · 1,177 people, phase 3 · Published May 2025, New England Journal of Medicine; FDA approved October 2025

68.8 mLless lung function lost over a year, with the higher dose

What was tested

Nerandomilast, a pill that blocks PDE4B, an enzyme involved in scarring, added to or used in place of existing antifibrotic drugs, against placebo.

What they found

Lung function (FVC) fell 114.7 mL with the higher dose and 183.5 mL with placebo over 52 weeks, a 68.8 mL difference.
Diarrhea was the main side effect (41.3% vs 16.0%).

What it means

The first new approved mechanism for IPF since 2014 (brand name Jascayd), usable alongside existing antifibrotics.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.